PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharmaceutical company dedicated to enhancing surgical outcomes, is set to participate in the Lytham Partners Spring 2025 Investor Conference on Thursday, May 29, 2025. The event will occur virtually, with PolyPid presenting a webcast at 10:15 a.m. ET. Interested parties can access the presentation via the conference homepage or directly through the provided link. The webcast will also be available for replay after the live event, allowing investors who cannot attend the opportunity to engage with the Company's insights.

In addition to the webcast, PolyPid’s management team will hold one-on-one meetings with investors throughout the conference. Those interested in setting up a personal meeting can coordinate through Lytham Partners via email or by registering for the event online.

PolyPid focuses on utilizing its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology, which enables the delivery of therapeutic drugs with controlled release rates tailored for surgical applications. The company’s lead product candidate, D-PLEX100, is currently in Phase 3 clinical trials aimed at preventing surgical site infections following abdominal colorectal surgeries. Furthermore, PolyPid is exploring the potential of OncoPLEX, in preclinical stages, for treating solid tumors, starting with glioblastoma.

For more information about PolyPid, including its technology and ongoing clinical trials, stakeholders are encouraged to visit the company’s official website and follow its social media channels. This conference represents a critical opportunity for PolyPid to showcase its innovative work and establish deeper connections with potential investors.

As PolyPid Ltd. (Nasdaq: PYPD) gears up for participation in the Lytham Partners Spring 2025 Investor Conference, scheduled for May 29, 2025, investors should closely monitor the company’s developments and positioning in the biopharma market. PolyPid specializes in enhanced surgical outcomes through its proprietary PLEX technology, which facilitates controlled and prolonged drug delivery. The company’s lead product, D-PLEX100, is currently undergoing a Phase 3 clinical trial aimed at preventing surgical site infections in colorectal surgeries, representing a significant potential market.

Investors should view PolyPid's involvement in the Lytham Partners conference as an opportunity to gauge the company’s progress and future strategies. The live webcast and one-on-one meetings with management will provide essential insights into the status of D-PLEX100 and other projects, such as the OncoPLEX initiative targeting solid tumors like glioblastoma. Given the increasing focus on targeted therapies and the management's commitment to innovation, PolyPid could play a pivotal role in addressing unmet medical needs in surgical care and oncology.

From a market perspective, stakeholders should assess PolyPid's clinical trial milestones and regulatory timelines, as successful outcomes can dramatically affect stock performance. Additionally, understanding the competitive landscape is critical, considering the increasing number of entrants in the biopharma sector focusing on similar delivery technologies.

In summary, PolyPid presents a speculative yet promising investment opportunity, particularly for those interested in biotech with innovative drug delivery modalities. Attending the conference can be a strategic move for investors seeking to understand the company’s trajectory and its potential impact on the evolving healthcare landscape. Investors are encouraged to utilize the information from the webcast and one-on-one sessions to make informed decisions on entering or adjusting their positions in PYPD.